The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Overview

Single-arm, open-label, single center study to assess the efficacy and safety of terbutaline plus danazol in patients with corticosteroid resistant/relapsed ITP.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 31, 2021

Detailed Description

Immune thrombocytopenia (ITP) is a severe bleeding disorder. Approximately 2/3 of patients achieve remission from first-line therapies. However, the underlying mechanism of corticosteroid-resistant or relapsed ITP is not well understood; thus, treatment remains a great challenge. β2-AR agonist terbutaline modulates T cell differentiation and effector cell function. A single center prospective study was performed in non-splenectomized ITP patients who were either resistant to a standard dose of corticosteroids or had relapsed. Patients were assigned to terbutaline plus danazol group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study, in order to assess the efficacy and safety of terbutaline plus danazol in patients with corticosteroid-resistant/relapsed ITP.

Interventions

  • Drug: Terbutaline
    • 2.5mg po tid for 12 weeks
  • Drug: Danazol
    • 200mg po bid for 12 weeks

Arms, Groups and Cohorts

  • Experimental: Terbutaline plus Danazol group
    • Terbutaline 2.5mg tid po plus danazol 200mg bid po for 12weeks

Clinical Trial Outcome Measures

Primary Measures

  • Sustained response
    • Time Frame: 6 months
    • The maintenance of platelet count ≥ 30 x 10^9/L, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 6-month follow-up. Interim analysis was scheduled at 50% through recruitment.

Secondary Measures

  • complete remission
    • Time Frame: 6 months
    • The number of participants (responders) with platelet count>=100×10^9/L (CR) and the absence of bleeding.
  • partial remission
    • Time Frame: 6 months
    • The number of participants (responders) with platelet count >=30×10^9/L and at least a 2-fold increase in the baseline count (PR) without the administration of any other platelet increasing therapy.
  • time to response
    • Time Frame: 6 months
    • Time to response was defined as the time from starting treatment to the time to achieve the response. Interim analysis
  • duration of response
    • Time Frame: 6 months
    • Duration of response was measured from the achievement of response to the loss of response.
  • incidence of treatment-emergent adverse events
    • Time Frame: 6 months
    • Adverse events were scaled according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Participating in This Clinical Trial

Inclusion Criteria

  • ITP confirmed by excluding other supervened causes of thrombocytopenia; – Platelet count of less than 30×10^9/L at enrollment; – Patients who did not achieve a sustained response to treatment with full dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation; – Subject has signed and dated written informed consent. – Fertile patients must use effective contraception during treatment and observational period – Negative pregnancy test. Exclusion Criteria:

  • Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus) – congestive heart failure – severe arrhythmia – nursing or pregnant women – aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of the normal threshold criteria – creatinine or serum bilirubin levels each 1•5 times or more than the normal range – active or previous malignancy – Unable to do blood routine test for the sake of time, distance, economic issues or other reasons. – diagnosis with any of the following diseases: chronic hypertension, hyperthyroidism, diabetes, or seizure disorder.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking University People’s Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Xiao Hui Zhang, Vice president of Peking Univeristy Institute of Hematology – Peking University People’s Hospital
  • Overall Official(s)
    • Xiaohui Zhang, MD, Principal Investigator, Peking University People’s Hospital, Peking University Insititute of Hematology
  • Overall Contact(s)
    • Xiaohui Zhang, MD, 010-88324981, zhangxh100@sina.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.